Immunological Landscape and Clinical Management of Rectal Cancer
- PMID: 26941741
- PMCID: PMC4761957
- DOI: 10.3389/fimmu.2016.00061
Immunological Landscape and Clinical Management of Rectal Cancer
Abstract
The clinical management of rectal cancer and colon cancer differs due to increased local relapses in rectal cancer. However, the current molecular classification does not differentiate rectal cancer and colon cancer as two different entities. In recent years, the impact of the specific immune microenvironment in cancer has attracted renewed interest and is currently recognized as one of the major determinants of clinical progression in a wide range of tumors. In colorectal cancer, the density of lymphocytic infiltration is associated with better overall survival. Due to the need for biomarkers of response to conventional treatment with chemoradiotherapy in rectal tumors, the immune status of rectal cancer emerges as a useful tool to improve the management of patients.
Keywords: chemotherapy; immune system; predictive factors; radiotherapy; rectal cancer.
Figures
Similar articles
-
EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe.Eur J Cancer. 2013 Sep;49(13):2784-90. doi: 10.1016/j.ejca.2013.04.032. Epub 2013 Jun 14. Eur J Cancer. 2013. PMID: 23769991
-
High dose rate brachytherapy as a boost after preoperative chemoradiotherapy for more advanced rectal tumours: the Clatterbridge experience.Clin Oncol (R Coll Radiol). 2007 Nov;19(9):711-9. doi: 10.1016/j.clon.2007.07.018. Epub 2007 Sep 19. Clin Oncol (R Coll Radiol). 2007. PMID: 17884396 Review.
-
Rectal and colon cancer: Not just a different anatomic site.Cancer Treat Rev. 2015 Sep;41(8):671-9. doi: 10.1016/j.ctrv.2015.06.007. Epub 2015 Jun 28. Cancer Treat Rev. 2015. PMID: 26145760 Review.
-
Aspects of survival from colorectal cancer in Denmark.Dan Med J. 2012 Apr;59(4):B4428. Dan Med J. 2012. PMID: 22459726
-
Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer.Biomed Res Int. 2015;2015:921435. doi: 10.1155/2015/921435. Epub 2015 Oct 4. Biomed Res Int. 2015. PMID: 26504848 Free PMC article. Review.
Cited by
-
Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer.Clin Transl Immunology. 2020 Feb 19;9(2):e1113. doi: 10.1002/cti2.1113. eCollection 2020. Clin Transl Immunology. 2020. PMID: 32076550 Free PMC article.
-
Immunotherapy in human colorectal cancer: Challenges and prospective.World J Gastroenterol. 2016 Jul 28;22(28):6362-72. doi: 10.3748/wjg.v22.i28.6362. World J Gastroenterol. 2016. PMID: 27605872 Free PMC article. Review.
-
Liquid biopsy approaches and immunotherapy in colorectal cancer for precision medicine: Are we there yet?Front Oncol. 2023 Jan 6;12:1023565. doi: 10.3389/fonc.2022.1023565. eCollection 2022. Front Oncol. 2023. PMID: 36686736 Free PMC article. Review.
-
Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects.Front Med. 2019 Feb;13(1):12-23. doi: 10.1007/s11684-019-0685-9. Epub 2019 Feb 22. Front Med. 2019. PMID: 30796606 Review.
-
A Distinct Innate Immune Signature of Early Onset Colorectal Cancer.Immunohorizons. 2021 Jun 23;5(6):489-499. doi: 10.4049/immunohorizons.2000092. Immunohorizons. 2021. PMID: 34162701 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources